Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage

Standard

Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage : Different Dynamics of Changes. / Fiedorowicz, Michal; Choragiewicz, Tomasz; Thaler, Sebastian; Schuettauf, Frank; Nowakowska, Dominika; Wojtunik, Kamila; Reibaldi, Michele; Avitabile, Teresio; Kocki, Tomasz; Turski, Waldemar A; Kaminska, Agnieszka; Grieb, Pawel; Zrenner, Eberhart; Rejdak, Robert; Toro, Mario Damiano.

In: FRONT PHYSIOL, Vol. 10, 2019, p. 1254.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Fiedorowicz, M, Choragiewicz, T, Thaler, S, Schuettauf, F, Nowakowska, D, Wojtunik, K, Reibaldi, M, Avitabile, T, Kocki, T, Turski, WA, Kaminska, A, Grieb, P, Zrenner, E, Rejdak, R & Toro, MD 2019, 'Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes', FRONT PHYSIOL, vol. 10, pp. 1254. https://doi.org/10.3389/fphys.2019.01254

APA

Fiedorowicz, M., Choragiewicz, T., Thaler, S., Schuettauf, F., Nowakowska, D., Wojtunik, K., Reibaldi, M., Avitabile, T., Kocki, T., Turski, W. A., Kaminska, A., Grieb, P., Zrenner, E., Rejdak, R., & Toro, M. D. (2019). Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes. FRONT PHYSIOL, 10, 1254. https://doi.org/10.3389/fphys.2019.01254

Vancouver

Bibtex

@article{e4a69fdcd33d4a3888a17c8282dedb0f,
title = "Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes",
abstract = "Kynurenines, products of tryptophan (TRP) metabolism, display neurotoxic (e.g., 3-hydroxykynurenine; 3-HK), or neuroprotective (e.g., kynurenic acid; KYNA) properties. Imbalance between the enzymes constituting the kynurenine pathway (KP) plays a role in several disease, including neurodegeneration. In this study, we track changes in concentrations of tryptophan and its selected metabolites after damage to retinal ganglion cells and link this data with expression of KP enzymes. Brown-Norway rats were subjected to intravitreal N-methyl-D-aspartate (NMDA) injection or partial optic nerve crush (PONC). Retinas were collected 2 and 7 days after the completion of PONC or NMDA injection. Concentrations of TRP, kynurenine (KYN), and KYNA were determined by high performance liquid chromatography (HPLC). Data on gene expression in the rat retina were extracted from GEO, public microarray experiments database. Two days after NMDA injection concentration of TRP decreased, while KYN and KYNA increased. At day 7 compared to day 2 decrease of KYN, KYNA and further reduction of TRP concentration were observed, but on day 7 KYN concentration was still elevated when compared to controls. At day 2 and 7 after NMDA injection no statistically significant alterations of 3-HK were observed. TRP and 3-HK concentration was higher in PONC group than in controls. However, both KYN and KYNA were lower. At day seven concentration of TRP, 3-HK, and KYN was higher, whereas concentration of KYNA declined. In vivo experiments showed that retinal damage or optic nerve lesion affect TRP metabolism via KP. However, the pattern of changes in metabolite concentrations was different depending on the model. In particular, in PONC KYNA and KYN levels were decreased and 3-HK elevated. These observations correspond with data on expression of genes encoding KP enzymes assessed after optic nerve crush or transection. After intraorbital optic nerve crush downregulation of KyatI and KyatIII between 24 h and 3 days after procedure was observed. Kmo expression was transiently upregulated (12 h after the procedures). After intraorbital optic nerve transsection (IONT) Kmo expression was upregulated after 48 h and 7 days, KyatI and KyatIII were downregulated after 12, 48 h, 7 days and upregulated after 15 days. Collected data point to the conclusion that development of therapeutic strategies targeting the KP could be beneficial in diseases involving retinal neurodegeneration.",
author = "Michal Fiedorowicz and Tomasz Choragiewicz and Sebastian Thaler and Frank Schuettauf and Dominika Nowakowska and Kamila Wojtunik and Michele Reibaldi and Teresio Avitabile and Tomasz Kocki and Turski, {Waldemar A} and Agnieszka Kaminska and Pawel Grieb and Eberhart Zrenner and Robert Rejdak and Toro, {Mario Damiano}",
note = "Copyright {\textcopyright} 2019 Fiedorowicz, Choragiewicz, Thaler, Schuettauf, Nowakowska, Wojtunik, Reibaldi, Avitabile, Kocki, Turski, Kaminska, Grieb, Zrenner, Rejdak and Toro.",
year = "2019",
doi = "10.3389/fphys.2019.01254",
language = "English",
volume = "10",
pages = "1254",
journal = "FRONT PHYSIOL",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage

T2 - Different Dynamics of Changes

AU - Fiedorowicz, Michal

AU - Choragiewicz, Tomasz

AU - Thaler, Sebastian

AU - Schuettauf, Frank

AU - Nowakowska, Dominika

AU - Wojtunik, Kamila

AU - Reibaldi, Michele

AU - Avitabile, Teresio

AU - Kocki, Tomasz

AU - Turski, Waldemar A

AU - Kaminska, Agnieszka

AU - Grieb, Pawel

AU - Zrenner, Eberhart

AU - Rejdak, Robert

AU - Toro, Mario Damiano

N1 - Copyright © 2019 Fiedorowicz, Choragiewicz, Thaler, Schuettauf, Nowakowska, Wojtunik, Reibaldi, Avitabile, Kocki, Turski, Kaminska, Grieb, Zrenner, Rejdak and Toro.

PY - 2019

Y1 - 2019

N2 - Kynurenines, products of tryptophan (TRP) metabolism, display neurotoxic (e.g., 3-hydroxykynurenine; 3-HK), or neuroprotective (e.g., kynurenic acid; KYNA) properties. Imbalance between the enzymes constituting the kynurenine pathway (KP) plays a role in several disease, including neurodegeneration. In this study, we track changes in concentrations of tryptophan and its selected metabolites after damage to retinal ganglion cells and link this data with expression of KP enzymes. Brown-Norway rats were subjected to intravitreal N-methyl-D-aspartate (NMDA) injection or partial optic nerve crush (PONC). Retinas were collected 2 and 7 days after the completion of PONC or NMDA injection. Concentrations of TRP, kynurenine (KYN), and KYNA were determined by high performance liquid chromatography (HPLC). Data on gene expression in the rat retina were extracted from GEO, public microarray experiments database. Two days after NMDA injection concentration of TRP decreased, while KYN and KYNA increased. At day 7 compared to day 2 decrease of KYN, KYNA and further reduction of TRP concentration were observed, but on day 7 KYN concentration was still elevated when compared to controls. At day 2 and 7 after NMDA injection no statistically significant alterations of 3-HK were observed. TRP and 3-HK concentration was higher in PONC group than in controls. However, both KYN and KYNA were lower. At day seven concentration of TRP, 3-HK, and KYN was higher, whereas concentration of KYNA declined. In vivo experiments showed that retinal damage or optic nerve lesion affect TRP metabolism via KP. However, the pattern of changes in metabolite concentrations was different depending on the model. In particular, in PONC KYNA and KYN levels were decreased and 3-HK elevated. These observations correspond with data on expression of genes encoding KP enzymes assessed after optic nerve crush or transection. After intraorbital optic nerve crush downregulation of KyatI and KyatIII between 24 h and 3 days after procedure was observed. Kmo expression was transiently upregulated (12 h after the procedures). After intraorbital optic nerve transsection (IONT) Kmo expression was upregulated after 48 h and 7 days, KyatI and KyatIII were downregulated after 12, 48 h, 7 days and upregulated after 15 days. Collected data point to the conclusion that development of therapeutic strategies targeting the KP could be beneficial in diseases involving retinal neurodegeneration.

AB - Kynurenines, products of tryptophan (TRP) metabolism, display neurotoxic (e.g., 3-hydroxykynurenine; 3-HK), or neuroprotective (e.g., kynurenic acid; KYNA) properties. Imbalance between the enzymes constituting the kynurenine pathway (KP) plays a role in several disease, including neurodegeneration. In this study, we track changes in concentrations of tryptophan and its selected metabolites after damage to retinal ganglion cells and link this data with expression of KP enzymes. Brown-Norway rats were subjected to intravitreal N-methyl-D-aspartate (NMDA) injection or partial optic nerve crush (PONC). Retinas were collected 2 and 7 days after the completion of PONC or NMDA injection. Concentrations of TRP, kynurenine (KYN), and KYNA were determined by high performance liquid chromatography (HPLC). Data on gene expression in the rat retina were extracted from GEO, public microarray experiments database. Two days after NMDA injection concentration of TRP decreased, while KYN and KYNA increased. At day 7 compared to day 2 decrease of KYN, KYNA and further reduction of TRP concentration were observed, but on day 7 KYN concentration was still elevated when compared to controls. At day 2 and 7 after NMDA injection no statistically significant alterations of 3-HK were observed. TRP and 3-HK concentration was higher in PONC group than in controls. However, both KYN and KYNA were lower. At day seven concentration of TRP, 3-HK, and KYN was higher, whereas concentration of KYNA declined. In vivo experiments showed that retinal damage or optic nerve lesion affect TRP metabolism via KP. However, the pattern of changes in metabolite concentrations was different depending on the model. In particular, in PONC KYNA and KYN levels were decreased and 3-HK elevated. These observations correspond with data on expression of genes encoding KP enzymes assessed after optic nerve crush or transection. After intraorbital optic nerve crush downregulation of KyatI and KyatIII between 24 h and 3 days after procedure was observed. Kmo expression was transiently upregulated (12 h after the procedures). After intraorbital optic nerve transsection (IONT) Kmo expression was upregulated after 48 h and 7 days, KyatI and KyatIII were downregulated after 12, 48 h, 7 days and upregulated after 15 days. Collected data point to the conclusion that development of therapeutic strategies targeting the KP could be beneficial in diseases involving retinal neurodegeneration.

U2 - 10.3389/fphys.2019.01254

DO - 10.3389/fphys.2019.01254

M3 - SCORING: Journal article

C2 - 31632294

VL - 10

SP - 1254

JO - FRONT PHYSIOL

JF - FRONT PHYSIOL

SN - 1664-042X

ER -